Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Clonal B-lymphocyte neoplasm of terminally differentiated plasma cells
Solitary = plasmacytoma
Brain/CNS is extramedullary plasmacytoma
Multifocal = multiple myeloma (MM)
Intracranial MM rare (1% of MM)
Can occur as solitary (primary) plasmacytoma or manifestation of systemic MM (secondary)
Secondary
Extension from osteolytic skull lesion > hematogenous spread
Primary CNS myeloma rare
Extraaxial dural-based nonosseous lesions
CNS “myelomatosis” involving leptomeninges &/or cranial nerves
Parenchymal masses (discrete nodules)
Best overall imaging tool: Radiography (skeletal survey)
Detects 80% of sites in 90% of patients
Up to 20% of radiographs and MR may be “normal”
CNS disease
Bone CT for calvaria, skull base
MR ± T1 C+ FS for nonosseous intracranial lesions
Surgical defect
Lytic metastasis
Hemangioma
Hyperparathyroidism
Peak onset = 65-70 years
1st primary bone malignancy in 4th-8th decades
Most common symptom: Bone pain (68%)
Prognosis
70% of plasmacytomas progress to MM
Solitary = plasmacytoma (PC)
Solitary plasmacytoma of bone
Extramedullary plasmacytoma (includes brain/CNS)
Multifocal = multiple myeloma (MM)
Clonal B-lymphocyte neoplasm of terminally differentiated plasma cells
Best diagnostic clue
Osteolytic skull lesion
Location
Intracranial MM rare (1% 0f MM)
Can occur as solitary (primary) plasmacytoma or manifestation of systemic MM (secondary)
In Waldenström macroglobulinemia (a.k.a. Bing-Neel syndrome)
Often widely disseminated at time of diagnosis
Secondary (extension from osseous lesions in calvaria, skull base, nose/paranasal sinuses > hematogenous spread) most common
Primary CNS myeloma rare
Extraaxial dural-based nonosseous lesions
CNS “myelomatosis” involving leptomeninges &/or cranial nerves
Parenchymal masses (discrete nodules)
Morphology
Focal, round or oval lesion(s)
Radiography
“Punched-out” lytic lesion(s) (90%)
Osteopenia/osteoporosis (10%)
Rarely sclerotic, except following therapy
NECT
“Punched-out” lytic lesion(s)
Meningeal myelomatosis: Marked hyperdensity
CECT
MM renal failure (RF) after contrast (0.6-1.25%)
0.15% in general population
Thus, not 100% risk-free but may be performed if necessary and patient well hydrated
Meningeal myelomatosis: Uniform enhancement
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here